These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32835900)

  • 21. COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
    Bsteh G; Assar H; Hegen H; Heschl B; Leutmezer F; Di Pauli F; Gradl C; Traxler G; Zulehner G; Rommer P; Wipfler P; Guger M; Enzinger C; Berger T;
    PLoS One; 2021; 16(7):e0255316. PubMed ID: 34314457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study.
    Zhang Y; Staker E; Cutter G; Krieger S; Miller AE
    Mult Scler Relat Disord; 2021 May; 50():102856. PubMed ID: 33662858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of patients hospitalized with COVID-19, H7N9 and H1N1.
    Deng LS; Yuan J; Ding L; Chen YL; Zhao CH; Chen GQ; Li XH; Li XH; Luo WT; Lan JF; Tan GY; Tang SH; Xia JY; Liu X
    Infect Dis Poverty; 2020 Dec; 9(1):163. PubMed ID: 33261654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome.
    Girmenia C; Gentile G; Micozzi A; Petrucci L; Malaspina F; Di Prima A; Baldacci E; Bianchi S; Pugliese P; Turriziani O; Antonelli G; Tombolini V; Foà R; Martelli M
    Acta Haematol; 2020; 143(6):574-582. PubMed ID: 32932252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MuSC-19 study: The Egyptian cohort.
    Zakaria M; Ponzano M; Schiavetti I; Carmisciano L; Nada M; AbdelNaseer M; Zamzam D; Masoud J; Aref H; Shalaby N; AbdelNaser A; Hamdy S; Saad M; Shehata H; Aly M; Kishk N; Hamdy E; Hassan A; Hashish A; Ahmed S; Foad M; Sormani MP
    Mult Scler Relat Disord; 2021 Nov; 56():103324. PubMed ID: 34656933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review.
    Barzegar M; Mirmosayyeb O; Gajarzadeh M; Afshari-Safavi A; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34016734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis.
    Michelena G; Casas M; Eizaguirre MB; Pita MC; Cohen L; Alonso R; Garcea O; Silva BA
    Mult Scler Relat Disord; 2022 Jan; 57():103368. PubMed ID: 35158474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prevalence of SARS-CoV-2 infection among symptomatic healthcare workers in a large university tertiary hospital in São Paulo, Brazil.
    Buonafine CP; Paiatto BNM; Leal FB; de Matos SF; de Morais CO; Guerra GG; Martuchelli MVV; Oliveira DBL; Durigon EL; Soares CP; Candido ED; Telezynski BL; Sáfadi MAP; Almeida FJ
    BMC Infect Dis; 2020 Dec; 20(1):917. PubMed ID: 33267836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and Outcomes of 241 Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection at Five New York City Medical Centers.
    Khoury R; Bernstein PS; Debolt C; Stone J; Sutton DM; Simpson LL; Limaye MA; Roman AS; Fazzari M; Penfield CA; Ferrara L; Lambert C; Nathan L; Wright R; Bianco A; Wagner B; Goffman D; Gyamfi-Bannerman C; Schweizer WE; Avila K; Khaksari B; Proehl M; Heitor F; Monro J; Keefe DL; D'Alton ME; Brodman M; Makhija SK; Dolan SM
    Obstet Gynecol; 2020 Aug; 136(2):273-282. PubMed ID: 32555034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
    De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
    Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A
    J Neurol; 2020 Dec; 267(12):3467-3475. PubMed ID: 32638107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thoracic imaging tests for the diagnosis of COVID-19.
    Salameh JP; Leeflang MM; Hooft L; Islam N; McGrath TA; van der Pol CB; Frank RA; Prager R; Hare SS; Dennie C; Spijker R; Deeks JJ; Dinnes J; Jenniskens K; Korevaar DA; Cohen JF; Van den Bruel A; Takwoingi Y; van de Wijgert J; Damen JA; Wang J; ; McInnes MD
    Cochrane Database Syst Rev; 2020 Sep; 9():CD013639. PubMed ID: 32997361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
    Bollo L; Guerra T; Bavaro DF; Monno L; Saracino A; Angarano G; Paolicelli D; Trojano M; Iaffaldano P
    J Neurol Sci; 2020 Sep; 416():117011. PubMed ID: 32650143
    [No Abstract]   [Full Text] [Related]  

  • 34. MSCOVID19: Using social media to achieve rapid dissemination of health information.
    Nesbitt C; Rath L; Yeh WZ; Zhong M; Wesselingh R; Monif M; Richards J; Minh VB; Jokubaitis VG; Skibina O; Butzkueven H; van der Walt A
    Mult Scler Relat Disord; 2020 Oct; 45():102338. PubMed ID: 32629402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic.
    Shi L; Lu ZA; Que JY; Huang XL; Liu L; Ran MS; Gong YM; Yuan K; Yan W; Sun YK; Shi J; Bao YP; Lu L
    JAMA Netw Open; 2020 Jul; 3(7):e2014053. PubMed ID: 32609353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak.
    Buonomo A; Brescia Morra V; Zappulo E; Lanzillo R; Gentile I; Montella E; Triassi M; Palladino R; Moccia M
    Mult Scler Relat Disord; 2020 Sep; 44():102282. PubMed ID: 32554288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East.
    Alroughani R; Inshasi J; Al-Hashel J; Alkhaboury J; Alsalti A; Al Suwaidi R; Hassino LH; Farouk Ahmed S
    J Clin Neurosci; 2022 May; 99():311-316. PubMed ID: 35339046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
    Rejdak K; Grieb P
    Mult Scler Relat Disord; 2020 Jul; 42():102163. PubMed ID: 32388458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.
    Hughes S; Troise O; Donaldson H; Mughal N; Moore LSP
    Clin Microbiol Infect; 2020 Oct; 26(10):1395-1399. PubMed ID: 32603803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis.
    Etemadifar M; Nouri H; Maracy MR; Akhavan Sigari A; Salari M; Blanco Y; Sepúlveda M; Zabalza A; Mahdavi S; Baratian M; Sedaghat N
    Rev Neurol (Paris); 2022; 178(1-2):121-128. PubMed ID: 34836608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.